For full-year 2013, the company forecast net product sales of $10 billion to $10.2 billion, which at least one analyst called "conservative" following record sales of more than $2.5 billion in the latest quarter.
"They beat handily on the top line and they beat on the bottom line by 2 cents," while suggesting that up to $100 million in sales were due to inventory stock-up, RBC Capital Markets analyst Michael Yee said.
Adjusting for one-time items, the company earned 50 cents a share during the quarter, exceeding the 48 cents a share forecast, on average, by analysts, according to Thomson Reuters.
Fourth-quarter net profit rose to $762.5 million, or 47 cents per share, from $665.1 million, or 43 cents per share, a year earlier.
Sales of HIV drug Atripla rose 6 percent to $917.5 million, which beat the $874 million expected by analysts, according to numbers published by ISI Group. Sales of HIV drug Truvada rose 12 percent to $832.7 million, surpassing analysts' estimate of $793 million.
Gilead is the world's largest maker of branded drugs to treat the human immunodeficiency virus, the cause of AIDS, but its near-term future is tightly linked to progress with an experimental hepatitis C drug.
The company said earlier Monday that two late-stage trials of its hepatitis C regimens met their goals and it remains on track for file for initial regulatory approvals this year.
Revenue for the quarter rose 18 percent to $2.59 billion. Analysts expected $2.43 billion, according to Thomson Reuters.
Shares of Gilead, which closed at $39.59 on the Nasdaq, were little changed at $39.60 in after hours trading.